1. Dual-probe ligation without PCR for fluorescent sandwich assay of EGFR nucleotide variants in magnetic gene capture platform
   Hwang-Shang Kou et al, 2023, Microchimica Acta CrossRef
2. The mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Next-generation Inhibitors and Approaches
   Murat Ihlamur et al, 2024, Current Molecular Medicine CrossRef
3. A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101)
   null null et al, 2018, International Journal of Clinical Oncology CrossRef
4. Molecular Pathology of Lung Cancer Cytology Specimens: A Concise Review
   Deepali Jain et al, 2018, Archives of Pathology & Laboratory Medicine CrossRef
5. Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis
   Hye Duck Choi et al, 2020, PLOS ONE CrossRef
6. Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors
   Zhen Zheng et al, 2017, Tumor Biology CrossRef
7. Hsa-Circ-0002360 Promotes the Development of Non-Small Cell Lung Cancer Cells by Regulating Specific E3 Ubiquitin Protein Ligase 2 Pathway Through miRNA-511-5p
   Hong Li et al, 2023, Journal of Biomedical Nanotechnology CrossRef